Risks of Ovarian, Breast, and Uterine Corpus Cancer in Women Receiving IVF Treatment
DOI:
https://doi.org/10.37375/sjms.v3i1.2865Keywords:
Assisted Reproductive Technology (ART), In Vitro Fertilization (IVF), Ovarian Cancer, Breast Cancer, Reproductive TherapyAbstract
Background A common treatment for infertility or genetic issues today is assisted reproductive technology (ART), which includes in vitro fertilization (IVF). Numerous studies have been done in this area in order to better understand the potential effects of this technique on women who undergo in vitro fertilization (IVF) and children born through IVF. This study is an updated meta-analysis to determine whether there is a causal relationship between different fertility treatments and ovarian, breast cancer. - Methods To reflect contemporary in vitro fertilization (IVF) practice, studies written during the last 20 years were included. Finding out whether women who receive hormonal reproductive treatment have an elevated risk of ovarian, breast cancer was the study's main objective. To find out if individual fertility therapies increased the risk of breast cancer, one of the secondary outcomes was to do so. Researcher observed first cancer diagnoses for ovarian, breast, and corpus uteri were compared to expected rates for each age, sex, and period. With the help of age, sex, and time-specific incidence rates, standardized incidence ratios (SIRs) were computed. Results On this subject, there are opposing viewpoints. According to some research, the risk of developing hormone-sensitive malignancies, such as ovarian, breast cancer, has somewhat increased. Breast cancer is one of the most common malignancies in women and the long-term use of IVF drugs can raise estrogen hormones and lead to excessive gene expression, increasing the risk of the disease. Conclusion There are a few dangers to be aware of as a result of the theory that lengthy IVF treatments may cause breast cancer in IVF candidates. Additionally, ovarian, breast cancer risk may be elevated in women with a favorable family history and associated inherited genes. The likely effects of the reproductive therapy approaches should therefore be explained to women who are candidates for IVF. Explained to women who are candidates for IVF.
References
Boivin J, Bunting L, Collins JA, Nygren KG. (2007). International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod, 22(6):1506–12.
Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. (2009). Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev, 7;(4):CD002249.
Ayhan A, Salman MC, Celik H, et al. (2004). Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand, 83(12):1104–11.
Mneimneh AS, Boulet SL, Sunderam S, et al. (2013). States Monitoring Assisted Reproductive Technology (SMART) Collaborative: data collection, linkage, dissemination, and use. J Womens Health (Larchmt), 22(7):571–7.
Jensen A, Sharif H, Olsen JH, Kjaer SK. (2008). Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol, 168(1):49–57.
Anstey EH, Shoemaker ML, Barrera CM, et al. (2017). Breastfeeding and Breast Cancer Risk Reduction: Implications for Black Mothers. Am J Prev Med, 53(3S1):S40–S46.
Lundberg FE, Johansson AL, Rodriguez-Wallberg K, et al. (2016). Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study. Breast Cancer Res, 18(1):36.
Burkman RT, Tang MT, Malone KE, et al. (2003). Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study. Fertil Steril, 79(4):844–51.
Kroener L, Dumesic D, Al-Safi Z. (2017). Use of fertility medications and cancer risk: a review and update. Curr Opin Obstet Gynecol, 29(4):195–201. - Farhud D, Zokaei S, Keykhaei M, et al. (2019). Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article. Iran J Public Health, 48(12):2124–2132.
Calderon-Margalit R, Friedlander Y, Yanetz R, et al. (2009). Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol, 169(3):365–75.
Reigstad MM, Larsen IK, Myklebust T, et al. (2015). Risk of breast cancer following fertility treatment--a registry based cohort study of parous women in Norway. Int J Cancer, 136(5):1140–8.
Petrangelo A, Czuzoj-Shulman N, Tulandi T, et al. (2018). Ovulation Induction for Infertility the Risk of Breast Cancer: A Population-Based Case-Control Study [11B]. bstetrics and Gynecology, 131(1):22S.
Williams CL, Jones ME, Swerdlow AJ, et al. (2018). Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ, 362:k2644.
Katz D, Paltiel O, Peretz T, et al. (2008). Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. Breast J, 14(6):517–22.
Pappo I, Lerner-Geva L, Halevy A, et al. (2008). The possible association between IVF and breast cancer incidence. Ann Surg Oncol, 15(4):1048–55.
Stewart LM, Holman CD, Hart R, et al. (2012). In vitro fertilization and breast cancer: is there cause for concern? Fertil Steril, 98(2):334–40.
Brekelmans CT. (2003). Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 15(1):63–8.
Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. (2006). Infertility, ovulation induction treatments and the incidence of breast cancer--a historical prospective cohort of women. Breast Cancer Res Treat, 100(2):201–12.
NIH (2018). Cancer Stat Facts: Female Breast Cancer. (ed)^(eds), National Institutes of Health (NIH).
Surakasula A, Nagarjunapu GC, Raghavaiah KV. (2014). A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. J Res Pharm Pract, 3(1):12–8.
Collaborative Group on Hormonal Factors in Breast Cancer (2012). Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol, 13(11):1141–51.
Collaborative Group on Hormonal Factors in Breast Cancer (2002). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet, 360(9328):187–95.
- Nindrea RD, Aryandono T, Lazuardi L, Dwiprahasto I. (2019). Family History of Breast Cancer and Breast Cancer Risk between Malays Ethnicity in Malaysia and Indonesia: A Meta-Analysis. Iran J Public Health, 48(2): 198–205.
Ramalhinho AC, Fonseca-Moutinho JA, Breitenfeld Granadeiro LA. (2012). Positive association of polymorphisms in estrogen biosynthesis gene, CYP19A1, and metabolism, GST, in breast cancer susceptibility. DNA Cell Biol, 31(6):1100–6.
Dos Santos EVW, Alves LNR, Louro ID. (2017). Steroid metabolism gene polymorphisms and their implications on breast and ovarian cancer prognosis. Genet Mol Res, 6;16(3):10.4238/gmr16039691.
Liehr JG. (2000). Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev, 21(1):40–54.
Bulzomi P, Bolli A, Galluzzo P, et al. (2010). Naringenin and 17beta-estradiol coadministration prevents hormone-induced human cancer cell growth. IUBMB Life, 62(1):51–60.
Sreeja S, Kumar TRS, Lakshmi BS, Sreeja S. (2012). Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. J Nutr Biochem, 23(7):725–32.
Lerner-Geva L, Geva E, Lessing JB, et al. (2003). The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer, 13(1):23–7.
Hughes E, Brown J, Collins JJ, Vanderkerchove P. (2010). Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev, 2010(1):CD000057.
Petrangelo A, Abenhaim H, Czuzoj-Shulman N, et al. (2018). Ovulation-Stimulating Fertility Treatments and the Long-Term Risk of Breast Cancer: a Case-Control Study Using the Clinical Practice Research Datalink. Journal of obstetrics and gynaecology Canada: JOGC, 40(6):849.
Cole L. (2014). Human Chorionic Gonadotropin (hCG). 2nd edn. Elsevier, pp. 446.
Taheripanah R, Balash F, Anbiaee R, et al. (2018). Breast Cancer and Ovulation Induction Treatments. Clin Breast Cancer, 18(5):395–399.
